ABIVAX Société Anonyme (NASDAQ:ABVX) will release its first-half earnings report after the closing bell on Monday, Sept. 21.
Analysts expect the Paris, France-based company to report a loss of $1.08 per share, on revenue of $1.86 million, according to Benzinga Pro.
On July 30, Abivax announced positive pre-NDA interaction with the FDA for Obefazimod.
ABVX shares rose 2.3% to close at $118.64 on Friday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
- Piper Sandler analyst Allison Bratzel maintained an Overweight rating and raised the price target from $165 to $175 on July 9, 2026. This analyst has an accuracy rate of 73%.
- Truist Securities analyst Gregory Renza maintained a Buy rating and increased the price target from $135 to $155 on July 2, 2026. This analyst has an accuracy rate of 63%.
- Citizens analyst Jason N. Butler maintained a Market Outperform rating with a price target of $187 on July 1, 2026. This analyst has an accuracy rate of 72%.
- Jefferies analyst Faisal Khurshid upgraded the stock from Hold to Buy and boosted the price target from $108 to $158 on June 30, 2026. This analyst has an accuracy rate of 75%.
- Wedbush analyst David Nierengarten maintained a Neutral rating and raised the price target from $90 to $110 on June 30, 2026. This analyst has an accuracy rate of 80%.
Considering buying ABVX stock? Here’s what analysts think:
Photo via Shutterstock